HC Wainwright & Co. Reiterates Buy on CARISMA Therapeutics, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a 'Buy' rating on CARISMA Therapeutics (NASDAQ:CARM) and maintained a $10 price target.
June 29, 2023 | 10:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on CARISMA Therapeutics and maintained a $10 price target, which could positively impact the stock in the short term.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiteration of a 'Buy' rating and maintenance of a $10 price target by HC Wainwright & Co. indicates their continued confidence in CARISMA Therapeutics, which could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100